Literature DB >> 11732416

Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes.

A H el Idrissi1, A Benkirane, M el Maadoudi, M Bouslikhane, J Berrada, A Zerouali.   

Abstract

To test the efficacy of rough Brucella strain vaccines in sheep, a vaccine recently developed in cattle (Brucella abortus strain RB51) was assessed in comparison with the conventional Rev. 1 vaccine. Forty-five ewes from twelve to fourteen months of age, from brucellosis-free flocks, were allotted to three groups of fifteen ewes each. Group one was vaccinated by the conjunctival route with 1.73 x 10(8) colony forming units (CFU) of Rev. 1 vaccine. Group two was vaccinated subcutaneously with 11 x 10(9) CFU of RB51 vaccine and group three was considered as a control. All sheep were challenged at two to three months of gestation with 5 x 10(7) CFU of virulent B. melitensis H38. Vaccination with RB51 vaccine did not result in the production of any antibodies against the O-side chain of lipopolysaccharide, as measured by conventional serological tests (Rose Bengal plate test and complement fixation test). Protection of sheep against abortion and excretion of virulent Brucella strain in vaginal fluid, aborted foetuses and/or non viable lambs at parturition and abortion was significantly lower than that afforded by Rev. 1 vaccine. The difference compared to the control group was not significant. Data from this study suggest that the RB51 vaccine used for cattle vaccination does not provide effective protection of sheep against abortion induced by B. melitensis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732416     DOI: 10.20506/rst.20.3.1305

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  11 in total

1.  In vivo differences in the virulence, pathogenicity, and induced protective immunity of wboA mutants from genetically different parent Brucella spp.

Authors:  Zhen Wang; Jianrui Niu; Shuangshan Wang; Yanli Lv; Qingmin Wu
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

2.  Protective properties of rifampin-resistant rough mutants of Brucella melitensis.

Authors:  R Adone; F Ciuchini; C Marianelli; M Tarantino; C Pistoia; G Marcon; P Petrucci; M Francia; G Riccardi; P Pasquali
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Production of the type IV secretion system differs among Brucella species as revealed with VirB5- and VirB8-specific antisera.

Authors:  Bruno Rouot; Maria-Teresa Alvarez-Martinez; Carine Marius; Pierrette Menanteau; Laurence Guilloteau; Rose-Anne Boigegrain; Robert Zumbihl; David O'Callaghan; Natalie Domke; Christian Baron
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 4.  Diagnosis of brucellosis in livestock and wildlife.

Authors:  Jacques Godfroid; Klaus Nielsen; Claude Saegerman
Journal:  Croat Med J       Date:  2010-08       Impact factor: 1.351

5.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

6.  Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection.

Authors:  Kaissar Tabynov; Abylai Sansyzbay; Zhailaubay Kydyrbayev; Bolat Yespembetov; Sholpan Ryskeldinova; Nadezhda Zinina; Nurika Assanzhanova; Kulaisan Sultankulova; Nurlan Sandybayev; Berik Khairullin; Irina Kuznetsova; Boris Ferko; Andrej Egorov
Journal:  Virol J       Date:  2014-04-10       Impact factor: 4.099

7.  Vaccine Candidate Brucella melitensis 16MΔvjbR Is Safe in a Pregnant Sheep Model and Confers Protection.

Authors:  Martha E Hensel; Daniel G Garcia-Gonzalez; Sankar P Chaki; Airn Hartwig; Paul W Gordy; Richard Bowen; Thomas A Ficht; Angela M Arenas-Gamboa
Journal:  mSphere       Date:  2020-05-13       Impact factor: 4.389

8.  Comparative assessment of passive surveillance in disease-free and endemic situation: example of Brucella melitensis surveillance in Switzerland and in Bosnia and Herzegovina.

Authors:  Daniela C Hadorn; Sabina Seric Haracic; Katharina D C Stärk
Journal:  BMC Vet Res       Date:  2008-12-22       Impact factor: 2.741

9.  Evaluation of shedding, tissue burdens, and humoral immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence vaccine strain Rev. 1.

Authors:  Jennifer L Higgins; Mercedes Gonzalez-Juarrero; Richard A Bowen
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

10.  Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.

Authors:  Aigerim Mailybayeva; Bolat Yespembetov; Sholpan Ryskeldinova; Nadezhda Zinina; Abylai Sansyzbay; Gourapura J Renukaradhya; Nikolai Petrovsky; Kaissar Tabynov
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.